Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cancer drugs
Biotech
BeOne shelves 5 cancer programs, halts ph. 2 arthritis trial
Four of the five cancer assets have been discontinued entirely, and the company is currently determining next steps for the arthritis candidate.
Darren Incorvaia
May 7, 2026 11:15am
Recursion's new CEO is bringing the AI outfit back to earth
May 6, 2026 6:30am
AbbVie dips into boiling RAS waters with $1.45B biobucks deal
Apr 28, 2026 10:01am
Rebranded biotech lands $125M for rescued Galapagos assets
Apr 28, 2026 7:00am
Astellas thins early pipeline, swaps out struggling gene therapy
Apr 27, 2026 10:38am
With global goals, Zai Lab offers China reality check
Apr 20, 2026 2:12pm
